MarginsXMarginsX
Home › Markets › Health Care › XENE

Xenon Pharmaceuticals Inc. Common Shares (XENE)

XENE trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$39.26
-3.01% on the day
Market cap
$3.9B
Mid cap
Revenue · 2025
$7.5M
Prior year not contiguous
Net income · 2025
-$345.9M
-4612.1% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1582313/000119312526076650/0001193125-26-076650-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerXENE on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryCanada
IPO year2014
SEC CIK0001582313
SEC industry codePharmaceutical Preparations
Incorporated inBC

Financials · 2025

LineValue
Revenue$7.5M
Net income-$345.9M
Operating income-$373.1M
Net margin-4612.1%
Operating margin-4974.3%
Revenue growthNo prior-year revenue to compare
Cash$199.2M
Total assets$633.2M
P/E (computed)Net income was not positive
P/S (computed)514.5×

Warning signs

Cash runway
2.8 months
$82.6M cash at September 30, 2026
Share count, 1 year
+27.2%
2025-10-30 to 2026-11-05 · +50.2% over 3 years
Going-concern doubt
No
10-Q filed November 9, 2026
Insider net buying, 12 months
-$23.0M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-09
Cash and burn$82.6M cash; operating cash flow -$89.0M a quarter.Report 2026-09-30
Shares outstanding98,284,734 (2026-11-05); 77,275,005 a year earlier; 65,429,711 three years earlier.Cover page 2026-11-05
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 3 424B5 takedowns, 3 at the marketLatest 2026-03-12
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorPricewaterhouseCoopers LLP, Boston, Massachusetts, United States; changed auditors 1 time in 24 months8-K 4.01 2025-03-05
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $23.0M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$0-$110.4M-$90.3M$82.6MNo debt tags$010-Q 2026-11-09
Q2 2026
2026-06-30
$0-$110.7M-$95.4M$119.5MNo debt tags$010-Q 2026-08-06
Q1 2026
2026-03-31
$0-$102.3M-$88.9M$545.9MNo debt tags$010-Q 2026-05-07
Q4 2025
2025-12-31
$0-$105.3M-$81.5M$199.2MNo debt tags$7.5M10-K 2026-02-26
Q3 2025
2025-09-30
$0-$90.9M-$71.8M$104.5MNo debt tags$7.5M10-Q 2026-11-09
Q2 2025
2025-06-30
$0-$84.7M-$64.2M$135.4MNo debt tags$7.5M10-Q 2026-08-06
Q1 2025
2025-03-31
$7.5M-$65.0M-$61.7M$116.7MNo debt tags$7.5M10-Q 2026-05-07
Q4 2024
2024-12-31
$0-$65.7M-$54.4M$142.7MNo debt tags$010-K 2026-02-26

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-03-12
Latest annual report10-K2026-02-26
Latest quarterly / interim10-Q2026-11-09
Latest current report8-K2026-11-09
Latest proxyDEFA14A2026-04-22

Source: SEC EDGAR submissions feed, 806 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+3.3%
1 month+17.6%
3 months-37.0%
Year to date-9.7%
1 year+1.1%
From 52-week high-43.0%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
OGNOrganon & Co. Common Stock$13.900.00%$3.7B
TNGXTango Therapeutics Inc.$24.17-5.22%$4.1B
ABCLAbCellera Biologics Inc. Common Shares$11.12-3.22%$3.6B
AMLXAmylyx Pharmaceuticals Inc.$27.80-8.22%$3.6B
PBLSParabilis Medicines Inc.$28.45+0.07%$3.5B
ELVNEnliven Therapeutics Inc.$47.62-2.42%$3.5B
IRONDisc Medicine Inc.$76.59-4.26%$3.5B
ARQTArcutis Biotherapeutics Inc.$27.15-3.93%$3.4B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier